Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

Pluristem Plans to Initiate a Phase I Trial in Rotator Cuff Injuries

HAIFA, Israel, April 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today it is expanding its presence in the orthopedic and
sports medicine markets with plans to initiate a Phase I clinical trial to
evaluate the safety and efficacy of the local administration of PLX cells to
patients suffering from injuries to tendons. This study planned will be a
randomized, double blind, placebo-controlled study to evaluate the safety and
efficacy of local intra-tendon injections of PLX-PAD cells to patients
suffering from rotator cuff tear requiring arthroscopic repair. The hypothesis
is that PLX-PAD cells will improve the post-operative structural and
functional status of the rotator cuff. This placebo controlled study will be
conducted in approximately 30 patients with a follow-up period of 6 months.

Tendinosis, sometimes called chronic tendonitis, is an accumulation over time
of micro tears of the connective tissue in and around the tendon that does not
heal properly. Tendinosis leads to pain and a reduced range of motion. If left
untreated, tendinosis may lead to reduced tensile strength that increases the
chance of tendon rupture. Current therapies involve prolonged rest and
immobilization. Rotator cuff tendinosis is a very common problem with more
than 50% of individuals older than 60 years presenting with at least a
partial-thickness rotator cuff tear. According to the American Academy of
Orthopedic Surgeons, each year approximately 200,000 Americans require surgery
related to repair of the rotator cuff. However full recovery after rotator
cuff surgery often takes 4 to 6 months and approximately 65% of the patients
undergoing rotator cuff repair will have a satisfactory result one year
following surgery.

"We have preclinical data illustrating the potential efficacy of PLX cells in
the treatment of tendon pathologies, conditions which impact a large segment
of the population. Intra-tendon injections of PLX cells will potentially allow
us to provide the focused delivery of therapeutic proteins in the treatment of
tendon injuries. This trial represents the expansion of our orthopedic and
sports injury franchise and is additive to our current ongoing study in muscle
injury," stated Zami Aberman, Pluristem's Chairman and CEO.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the Phase I
Trial in rotator cuff injuries which we plan to initiate, when we discuss the
hypothesis that PLX-PAD cells will improve the post-operative structural and
functional status, or when we say that Intra-tendon injections of PLX cells
will potentially allow us to provide the focused delivery of therapeutic
proteins in the treatment of tendon injuries, we are using forward-looking
statements. These forward-looking statements and their implications are based
on the current expectations of the management of Pluristem only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; we may encounter delays or
obstacles in launching and/or successfully completing our clinical trials; our
products may not be approved by regulatory agencies, our technology may not be
validated as we progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key employees
whose knowledge is essential to the development of our products; unforeseen
scientific difficulties may develop with our process; our products may wind up
being more expensive than we anticipate; results in the laboratory may not
translate to equally good results in real surgical settings; results of
preclinical studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm recipients;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share and pressure on
pricing resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.